



Published in final edited form as:

*Exp Biol Med (Maywood)*. 2012 February 1; 237(2): 111–118. doi:10.1258/ebm.2011.011208.

## Canonical Transient Receptor Potential (TRPC) Channels in Diabetes

**Sarabeth Graham, Joseph P. Yuan, and Rong Ma\***

Department of Integrative Physiology and Cardiovascular Research Institute University of North Texas Health Science Center, Fort Worth, TX, USA 76107

### Abstract

Canonical Transient Receptor Potential (TRPC) channel proteins have been identified as downstream molecules in a G protein coupled receptor signaling pathway and are involved in a variety of cell functions due to their ability to regulate intracellular calcium signaling. TRPC channel physiology has been an increasingly interesting and relevant topic over the past decade, and the outcomes from various studies have advanced our understanding of TRPC function in the normal state. Recently, attention has turned to whether or not TRPC proteins are implicated in diseases. Emerging evidence suggests a significant contribution of several isoforms of TRPC proteins to cardiovascular as well as renal diseases. This review focuses on the implication of TRPC proteins as they pertain to diabetes. We summarize the recent findings by other investigators as well as ourselves and additionally discuss the important role of TRPC proteins in the development of various diabetic complications, such as diabetic nephropathy and diabetic vasculopathy. The underlying mechanisms which contribute to these complications are also outlined. Lastly, we elaborate on the role of TRPC proteins as a potential therapeutic target for treating diabetes-associated diseases.

### Keywords

TRPC; Diabetes; Diabetic complications; Calcium

### Introduction

Canonical transient receptor potential (TRPC) channels, a seven member subfamily of the transient receptor potential (TRP) family of ion channels, are present in a wide variety of tissues. Accumulating evidence demonstrated that all TRPC proteins have both physiological as well as pathophysiological relevance.<sup>1</sup> Physiologically, these nonselective cation channels can function either as receptor-operated (ROC) or as store-operated (SOC) channels, which upon activation increase the intracellular Ca<sup>2+</sup> concentration. As a result, TRPC channels contribute to the function of various systems and organs, including the cardiovascular system, the nervous system, the kidneys, and the liver.<sup>1–3</sup> In addition to the physiological roles for these channels, mutation or dysregulation of the channels leads to the development of several different disorders, some of which include focal segmental glomerulosclerosis, diabetic complications, cardiac hypertrophy, and impaired cognitive

\*To whom correspondence should be addressed: RES-302G, 3500 Camp Bowie Blvd., Department of Integrative Physiology, University of North Texas Health Science Center, Fort Worth, TX 76107, Tel: 817-735-2516; Fax: 817-735-5084, rong.ma@unthsc.edu.

#### Author contributions

SG and RM wrote the manuscript. JPY edited the manuscript.

function.<sup>4-8</sup> The widespread effects of TRPC channel dysregulation indicate their critical biological importance.

Recently, an association between altered TRPC channel function and/or expression with the development of various diabetic complications has garnered the attention of many investigators.<sup>4, 5, 9-15</sup> Considering their ubiquitous distribution in biological systems and their critical role in cell signaling pathways, TRPC channels hold promise as a therapeutic target for treating various organ and system disorders associated with diabetes. The goal of this review is to identify and characterize TRPC channels which are affected by chronic high glucose and/or diabetes in an effort to compile what has been described to date. The results are summarized in Table 1 as an easy reference guide for the current literature.

## TRPC channels and diabetes

### Diabetic Nephropathy

Diabetic nephropathy (DN) occurs in approximately 40% of all diabetics and is the leading cause of end stage renal disease in America.<sup>16</sup> Accumulating evidence suggests that DN is one of the most prevalent diseases directly linked to TRPC channel dysfunction. Niehof et al. reported a downregulation of TRPC1 mRNA as well as protein in Zucker diabetic fatty (ZDF) rats (an animal model for Type 2 diabetes mellitus), in streptozotocin (STZ) injected rats (an animal model for Type 1 diabetes mellitus), and in kidney biopsies from patients with DN.<sup>14</sup> In a mouse model (db/db mice) of Type 2 diabetes, Zhang et al found that TRPC1 mRNA in kidney tissues was slightly reduced after 12 weeks, but significantly reduced by 26 weeks compared to their controls.<sup>12</sup> Additionally, we did not find any significant change in TRPC1 protein expression in freshly isolated glomeruli from rats 2 weeks after STZ injection.<sup>5</sup> These findings promote the idea that diminished TRPC1 expression occurs in the later stages of DN. Although these studies were descriptive and did not demonstrate a cause-and-effect relationship between the abnormal expression of TRPC1 and kidney dysfunction, the specific location of the TRPC1 gene on human chromosome 3q22-24, a region linked to DN<sup>17-19</sup> alludes to a possible role in initiating DN.<sup>3, 20, 21</sup>

In addition to TRPC1, TRPC6 may also be dysfunctional in diabetes and the abnormal TRPC6 expression or activity in kidney cells may contribute to the development of DN. Earlier studies from our group have demonstrated that chronic high glucose in glomerular mesangial cells as well as diabetes in STZ rats led to a downregulation of TRPC6 mRNA as well as protein.<sup>5</sup> However, the other TRPC isoforms, such as TRPC1 and TRPC3, did not have significant changes. The decrease in TRPC6 protein expression appeared specific for glomerular tissue because the expression of this protein did not change in the aorta but significantly increased in the whole heart tissue isolated from those STZ rats.<sup>22</sup> Since our study was conducted in rats only 2 weeks after STZ injection, the decrease in abundance of TRPC6 protein might indicate an early change in the development of DN.

Both TRPC1 and TRPC6 are broadly distributed in the kidneys.<sup>3, 21, 23</sup> Specifically, both TRPCs play an important role in regulating glomerular filtration by regulating contractile function of the glomerular mesangial cells.<sup>20, 22</sup> In diabetes, mesangial contractile function is impaired, and reduced Ca<sup>2+</sup> influx is believed to be a major contributing factor to the hypocontractility.<sup>24-26</sup> Our functional studies in cultured mesangial cells have demonstrated that both TRPC1 and TRPC6 participate in agonist-stimulated Ca<sup>2+</sup> entry through store-operated and/or receptor-operated mechanisms.<sup>20, 22</sup> It is known that different TRPC isoforms can interact with each other to form heteromeric channels,<sup>27, 28</sup> We have previously shown that TRPC1 and TRPC6 were colocalized and physically interacted with each other in mesangial cells.<sup>21</sup> Thus, the heterotetramers of TRPC1 and TRPC6 may constitute the native functional channels in glomerular mesangial cells. A reduced number of

either TRPC1 or TRPC6 channels or both in mesangial cells would lead to impairment of  $\text{Ca}^{2+}$  influx and consequently, disturbs intracellular  $\text{Ca}^{2+}$  homeostasis, which eventually results in changes in glomerular hemodynamics in diabetes.

## Diabetic Vasculopathy

**i. Alteration in the contractile response of blood vessels**—Abnormalities in vascular reactivity and function are common in diabetes.<sup>29–31</sup> Dysfunction of both vascular endothelial cells and vascular smooth muscle cells (VSMC) contributes to the diabetes-associated vascular complications.<sup>30, 32–36</sup> Vascular smooth muscle dysfunction is characterized by impaired relaxation to vasodilators or an exacerbated response to vasoconstrictors.<sup>30, 32–36</sup> All 7 members of TRPC are expressed in endothelial cells and at least 4 isoforms (TRPC1, 3, 4 and 6) are also found in VSMCs.<sup>37, 38</sup> Therefore, abnormal function or expression of a particular TRPC in vascular tissues could lead to blood vessel dysfunction. A recent study by Chung et al. reported that both TRPC1 and TRPC6 protein expression in saphenous veins from patients with Type 2 diabetes were significantly decreased however their mRNA levels remained unchanged. TRPC4 mRNA expression was elevated in the diabetic vessel; however its protein level was not significantly different from that in the non-diabetic saphenous veins.<sup>9</sup> These findings suggest that a post-transcriptional process in TRPCs is altered in diabetic vasculatures. Although TRPC protein expressions were reduced or unchanged, the contraction initiated by cyclopiazonic acid, an activator of store-operated  $\text{Ca}^{2+}$  channels, was significantly higher in the saphenous veins from diabetic patients than in the vessels from non-diabetic subjects. The authors deduced that the augmented contraction in the diabetic vessels was attributed to increased channel activity, but not due to an altered number of TRPC channels. This conclusion is highly speculative because whether TRPC proteins are truly and solely the molecular components of store-operated  $\text{Ca}^{2+}$  channels remain highly debatable.<sup>6, 39, 40</sup> Moreover, the authors did not examine STIM1 and Orai1, two proteins that have been acknowledged to play a key role in controlling store-operated  $\text{Ca}^{2+}$  entry.<sup>41–43</sup> Changes in protein expression of both STIM1 and Orai1 in diabetes have been reported.<sup>44</sup>

Contradictory findings were reported in caudal artery smooth muscle from Goto-Kakizaki (GK) rats,<sup>15</sup> an established model of Type 2 diabetes mellitus by selective breeding from originally non-diabetic Wistar rats.<sup>45</sup> Different from other diabetic animal models, GK rats show a significantly lower systolic blood pressure compared to that in Wistar rats.<sup>46</sup> Consistent with a low systolic blood pressure, the contraction of endothelium-denuded caudal artery strips from GK rats in response to cyclopiazonic acid and cirazoline ( $\alpha 1$ -adrenoceptor agonist) was significantly depressed when compared to vessels from non-diabetic Wistar rats.<sup>15</sup> Surprisingly, the expression of TRPC1, 4 and 6 was significantly increased in the diabetic caudal artery smooth muscle. Considering that TRPC proteins form homo- and heteromeric channels which have distinct electrophysiological properties,<sup>27, 28, 47, 48</sup> the paradoxical phenomenon (impairment of the store-operated  $\text{Ca}^{2+}$  entry-mediated vessel contraction and upregulation of TRPC protein expression) could be interpreted as abnormal assembly of endogenous TRPC proteins in GK rat smooth muscle. However, as the authors stated, the possibility that altered expression of STIM1 and Orai1 also contribute to the impaired vessel contraction in diabetes could not be excluded.

Another contributor to the abnormal contractile response of blood vessels in diabetes is endothelial dysfunction.<sup>49</sup> A  $\text{Ca}^{2+}$  dependent nitric oxide mechanism has been proposed to underlie the impaired endothelial function.<sup>50</sup> As candidates of receptor-operated and/or store-operated  $\text{Ca}^{2+}$  channels in endothelial cells,<sup>37</sup> TRPCs may be associated with the pathological changes in diabetes by disturbing  $\text{Ca}^{2+}$  homeostasis in vascular endothelial cells. A recent study by Bishara et al demonstrated that among the 4 TRPC isoforms

expressed in cultured bovine aortic endothelial cells (TRPC1, 3, 4, and 6), only the TRPC1 protein level was significantly increased in response to chronic treatment with high glucose,<sup>10</sup> and this higher level of TRPC1 protein was associated with an augmented  $\text{Ca}^{2+}$  influx induced by  $\text{Ca}^{2+}$  store-depletion.<sup>10</sup> Although a link between the high glucose-induced increase in TRPC1 protein/ $\text{Ca}^{2+}$  entry and endothelial dysfunction can not be established with certainty, this study provides a clue that TRPC1 is a potential therapeutic target for the treatment of vascular complications of diabetes.

**ii. Atherosclerosis**—Diabetes is an independent risk factor for the development of atherosclerosis, clinically resulting in coronary heart disease, increased risk of cerebrovascular disease, and severe peripheral vascular disease.<sup>51, 52</sup> In diabetes, impairment of the endothelium, aggregating platelets, adhesion and migration of monocytes to the vascular wall, and migration and proliferation of smooth muscle cells are all key factors for the initiation and progression of atherosclerosis.<sup>53, 54</sup> It has been demonstrated that diabetes alters TRPC protein expression in vascular myocytes. In cultured aortic smooth muscle cells from diabetic GK rats, Evans et al reported that TRPC4 protein was detected at significantly greater levels, but TRPC6 protein was dramatically reduced compared to that in the cells from non-diabetic WKY rats.<sup>13</sup> There was no difference in TRPC1 or TRPC5 expression between the two groups.<sup>13</sup> Functional experiments demonstrated that Ang II-induced  $\text{Ca}^{2+}$  influx was significantly enhanced in the GK aortic smooth muscle cells and that this  $\text{Ca}^{2+}$  entry response was not affected by inhibition of voltage-operated  $\text{Ca}^{2+}$  channels. Instead this  $\text{Ca}^{2+}$  entry was depressed by oleoyl-2-acetyl-sn-glycerol, an activator of TRPC3/6/7 channels and an inhibitor to TRPC4/5 channels.<sup>55</sup> Since TRPC3 gene expression was undetectable in both WKY and GK VSMCs and TRPC6 protein was significantly down-regulated in GK, the authors concluded that the elevated  $\text{Ca}^{2+}$  influx in the diabetic GK aortic VSMCs was attributed to overactive TRPC1/4/5 channels. Their findings in the VSMCs from diabetic aorta are consistent with earlier reports in VSMCs of atherosclerotic vessels where a shift in  $\text{Ca}^{2+}$  channel expression occurred with voltage-operated  $\text{Ca}^{2+}$  channels down-regulated and TRPC protein expression increased.<sup>56, 57</sup> Presumably, this shift in  $\text{Ca}^{2+}$  channel expression is associated with dedifferentiation of VSMCs from their normal contractile phenotype to a synthetic, phenotypically modulated cell, which is a key step in atherosclerosis. This is also true for atherosclerotic coronary artery disease, which has high prevalence and severity in patients with diabetes mellitus.<sup>53, 58</sup> Using Ossabaw swine as an animal model of metabolic syndrome (pre-diabetes), Edwards et al showed that metabolic syndrome increased TRPC1 (also STIM1) protein expression in coronary VSMCs, which is associated with elevated store-operated  $\text{Ca}^{2+}$  entry and greater atherosclerotic coronary artery disease.<sup>59</sup> Exercise training decreased TRPC1 (also STIM1) protein in the smooth muscle cells with a simultaneous decrease in  $\text{Ca}^{2+}$  entry and atherosclerosis in the coronary artery. These data suggest an important role for TRPC1-mediated store-operated  $\text{Ca}^{2+}$  entry in coronary artery VSMCs in the development of atherosclerosis in diabetes.

As described previously,<sup>10</sup> high glucose significantly increased the abundance of TRPC1 protein in aortic endothelial cells and, consequently, enhanced agonist-stimulated  $\text{Ca}^{2+}$  entry. Therefore, altered TRPC channel-mediated  $\text{Ca}^{2+}$  signaling may contribute to atherosclerosis by compromising the integrity of the endothelial barrier which permits more direct interaction of the diabetic milieu with smooth muscle. Another role for endothelial cells in the initiation and progression of atherosclerotic lesions is recruitment of circulating monocytes to the arterial intima by upregulation of vascular cell adhesion molecule 1 (VCAM-1) on the endothelial cells.<sup>60</sup> TRPC3 may be involved in the signaling pathway for VCAM-1 upregulation. In human coronary artery endothelial cells, ATP, a stimulus for atherosclerosis, increased the expression of TRPC3 protein. This was in correlation with augmented TRPC3-dependent constitutive and ATP-stimulated  $\text{Ca}^{2+}$  influx as well as

upregulation of VCAM-1.<sup>61</sup> TRPC3 knock-down resulted in a dramatic reduction of ATP-induced VCAM-1 and monocyte adhesion to the endothelial cells. These findings suggest a potential pathophysiological role for TRPC3 in coronary artery atherosclerosis.

As mentioned above, recruitment of circulating monocytes to the arterial intima is a crucial event in the initiation, progression, and fate of the atherosclerotic lesion. Monocyte adhesion to the vascular wall is determined by the interaction between monocytes and the vascular endothelial cells.<sup>60</sup> Therefore, the activity of the monocyte itself also affects the adhesion process. Wuensch et al. recently reported that high glucose treatment significantly increased TRPC3 and TRPC6 protein expression in human monocytes.<sup>11</sup> The expression of TRPC1 and TRPC5 in monocytes also increased at the mRNA level. Importantly, TRPC6 mRNA, but not TRPC1, TRPC3, or TRPC5 mRNA was significantly higher in monocytes from patients with Type 2 diabetes as compared with control subjects.<sup>11</sup> Since monocyte activation is a  $Ca^{2+}$  regulated process and a key initial event in the pathogenesis of diabetic atherosclerosis,<sup>62–64</sup> elevated TRPC3 and TRPC6 protein expression in monocytes would increase the risk of developing diabetic cardiovascular diseases by enhancing  $Ca^{2+}$  influx.

Platelet hyperaggregability and hyperactivity due to an enhanced  $Ca^{2+}$  entry plays an important role in the development of cardiovascular complications in diabetes mellitus.<sup>65, 66</sup> Recent studies have identified several  $Ca^{2+}$  signaling proteins, including TRPC1, 3, and 6 as contributors to agonist-stimulated  $Ca^{2+}$  entry in platelets.<sup>67–70</sup> In platelets isolated from patients with Type 2 diabetes, Zbidi et al., found that TRPC6 protein expression was decreased,<sup>44</sup> however TRPC3 (also STIM1 and Orai1) protein was significantly upregulated as compared with the platelets from control subjects. There was no difference in TRPC1 protein expression levels between diabetic and control platelets. This study suggests that an upregulation of TRPC3 as well as STIM1 and Orai1 proteins are responsible for the enhanced  $Ca^{2+}$  entry in diabetic platelets, which was reported in their previous observations.<sup>66, 71</sup> Another finding reported by Liu et al showed that TRPC6 protein expression increased in the platelets from patients with Type 2 diabetes mellitus compared to non-diabetic individuals.<sup>72</sup> Treatment of platelets from healthy humans with high glucose increased TRPC6 protein expression on the platelet surface in a time- and concentration-dependent manner, which was accompanied by an increased OAG-induced  $Ca^{2+}$  influx, whereas TRPC1, TRPC3, TRPC4, and TRPC5 were unchanged.<sup>72</sup> The exact mechanism for the discrepancy between the two studies is unclear, but could be the differences in protein expression analysis (western blot vs. immunofluorescence), recruitment of diabetic subjects, and severity and stages of diabetes mellitus.

In summary, various TRPC channels contribute to the development of cardiovascular complications of diabetes mellitus by altering  $Ca^{2+}$  signaling in multiple cell types and cell fragments in vasculature and circulation. A diagram depicting a TRPC mechanism for promoting diabetic vasculopathy is presented in figure 1.

### Diabetic Neuropathy

Erectile dysfunction in diabetic patients and diabetic animal models is associated with a reproducible autonomic neuropathy and a decline in erectile capacity.<sup>73–75</sup> The diabetes-related erectile dysfunction is presumably related to heightened contractility and/or an impaired relaxation of corporal smooth muscle. TRPC6 channels were recently reported to modulate the tone of the corporal smooth muscle by regulating intracellular  $Ca^{2+}$  concentration.<sup>76</sup> Overexpression of dominant negative TRPC6 channels in human corporal smooth muscle cells significantly reduced the agonist-stimulated  $Ca^{2+}$  response. *In vivo* gene transfer of dominant negative TRPC6 into smooth muscle of the corpus cavernosum in STZ rats dramatically restored erectile function in those diabetic rats.<sup>76</sup> This study suggests

that enhanced TRPC6 channel expression and/or activity in the corpus cavernosum of the penis may underlie erectile dysfunction in diabetes.

## Mechanisms involved in TRPC dysregulation in diabetes

Multiple pathways are involved in TRPC channel dysfunction and diabetes since the scope of diabetes and diabetes-related complications is so broad and since the TRPC channels are so diverse in terms of distribution and function. Using pharmacological and molecular biological tools, we have recently proposed a reactive oxygen species (ROS)-protein kinase C (PKC) pathway which contributes to the diabetes-induced TRPC6 protein decrease observed in human mesangial cells.<sup>22</sup> In this cell system, chronic high glucose increases NADPH oxidase activity and/or expression level, which results in overproduction of intracellular ROS.<sup>22</sup> Increased ROS levels then activate PKC, which is capable of either directly or indirectly downregulating TRPC6 in mesangial cells. The PKC family consists of at least 12 isoforms.<sup>77</sup> Mesangial cells are known to express PKC $\alpha$ ,  $\beta$ I,  $\beta$ II,  $\gamma$ ,  $\delta$ ,  $\theta$ ,  $\zeta$ , and  $\mu$ .<sup>78-80</sup> It appears that PKC $\alpha$  is one of the isoforms, if not the sole isoform, responsible for mediating the high glucose and ROS effect on TRPC6 expression. An inhibitor (Gö6976) for both PKC $\alpha$  and  $\beta$ , but not an inhibitor (LY333531) for PKC $\beta$  alone significantly blocked both the high glucose and ROS-induced TRPC6 decrease.<sup>22</sup>

Wuensch et al., have also described a ROS mechanism for HG-induced changes in TRPC mRNA or protein expression in human monocytes. Different from our findings in glomerular mesangial cells, elevated ROS levels in monocytes leads to increases in TRPC expression.<sup>11</sup> It is possible that different cell types and conditions could utilize diverging pathways originating at increased ROS levels, which lead to the upregulation or downregulation of a particular TRPC isoform. Overproduction of ROS has been previously described as one common pathological process in diabetes as well as in cells cultured in chronic high glucose.<sup>81-84</sup> Additionally, there has been an increasing amount of evidence to support the role of ROS in the development of diabetic complications, such as DN.<sup>85-87</sup> Thus, oxidative stress may be a general mechanism for diabetes-associated TRPC protein dysregulation.

Both Niehof et al. and Zhang et al. have described a pathway whereby a specific gene, hepatic nuclear factor 4-alpha (*HNF4 $\alpha$* ), becomes dysfunctional as a result of exposure to diabetes or high glucose.<sup>14</sup> Due to *HNF4 $\alpha$*  impairment, *TRPC1* gene expression is reduced, and the abundance of TRPC1 protein is decreased in kidneys, which ultimately results in the development of DN.

Liu et al. proposed another mechanism whereby diabetes/high glucose alters TRPC expression. They described a pathway where high glucose directly activates a phosphatidylinositol 3-kinase which then promotes TRPC6 channel translocation to the cell surface and thus increases TRPC6 protein expression in the cell membrane.<sup>72</sup> This increased TRPC6 protein expression in the plasma membrane contributes to atherosclerosis and increased thrombotic events, both of which are major vascular complications in diabetes.

## Closing remarks

The studies reviewed in this article provide evidence that diabetes is associated with a global change in abundance of TRPC proteins. However, some results from different groups appear to contradict each other. In this regard, it is worth noting that in many instances the animal species, cell/tissue types, stages and severity of diabetes, and glucose concentrations differ between sets of experiments. Furthermore, there are likely several different pathways mediating the diabetes-related alteration of TRPC expression. These intracellular pathways may be cell type specific and therefore contribute to the varying TRPC responses to high

glucose or diabetes in different type of cells. Also, the mechanism for the diabetes-associated TRPC dysregulation is currently unclear. Although several molecules, such as ROS, have been proposed to be mediators in this pathological process,<sup>14, 22, 72</sup> how they upregulate or downregulate a particular subtype of TRPCs in diabetes is unknown. Moreover, whether the alteration of TRPC expression is the cause or a result of diabetic diseases has yet to be determined. Nevertheless, as a result of more information becoming known regarding TRPC channels and their role in diabetes, development of specific TRPC inhibitors may be a potential therapeutic option for various diabetic complications. Additionally, treatments utilizing various gene silencing methods for TRPCs or for genes upstream of the proteins could also be useful for diabetic patients. Given the global pandemic of diabetes, searching for additional therapeutic agents is essential to reduce the immense burden of the disease. TRPC channels may be a novel therapeutic target in treating diabetes and its complications.

## Acknowledgments

Part of the work described in this article was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (5 RO1 DK079968-01A2, R. Ma).

## References

1. Abramowitz J, Birnbaumer L. Physiology and pathophysiology of canonical transient receptor potential channels. *FASEB J*. 2009; 23:297–328. [PubMed: 18940894]
2. Clapham DE. TRP channels as cellular sensors. *Nature*. 2003; 426:517–524. [PubMed: 14654832]
3. Goel M, Sinkins WG, Zuo CD, Schilling WP. Identification and localization of TRPC channels in rat kidney. *Am J Physiol Renal Physiol*. 2006; 290:F1241–F1252. [PubMed: 16303855]
4. Liu D, Zhu Z, Tepel M. The role of transient receptor potential channels in metabolic syndrome. *Hypertens Res*. 2008; 31:1989–1995. [PubMed: 19098369]
5. Graham S, Ding M, Sours-Brothers S, Yorio T, Ma JX, Ma R. Downregulation of TRPC6 protein expression by high glucose, a possible mechanism for the impaired Ca<sup>2+</sup> signaling in glomerular mesangial cells. *Am J Physiol Renal Physiol*. 2007; 293:F1381–F1390. [PubMed: 17699555]
6. Venkatchalam K, Montell C. TRP channels. *Annu Rev Biochem*. 2007; 76:387–417. [PubMed: 17579562]
7. Hsu Y, Hoenderop JGJ, Bindels RJM. TRP channels in kidney disease. *Biochimica et Biophysica Acta*. 2007; 1772:928–936. [PubMed: 17346947]
8. Dietrich A, Chubanov V, Gudermann T. Renal TRP channels. *J Am Soc Nephrol*. 2010; 21:736–744. [PubMed: 20395377]
9. Chung AW, Yeung KA, Chum E, Okon EB, van Breemen C. Diabetes modulates capacitative calcium entry and expression of transient receptor potential canonical channels in human saphenous vein. *Eur J Pharmacol*. 2009; 613:114–118. [PubMed: 19393642]
10. Bishara NB, Ding H. Glucose enhances expression of TRPC1 and calcium entry in endothelial cells. *Am J Physiol Heart Circ Physiol*. 2010; 298:H171–H178. [PubMed: 19855058]
11. Wuensch T, Thilo F, Krueger K, Scholze A, Ristow M, Tepel M. High glucose-induced oxidative stress increases transient receptor potential (TRP) channel expression in human monocytes. *Diabetes*. 2010; 59:844–849. [PubMed: 20068131]
12. Zhang D, Freedman BI, Flekac M, Santos E, Hicks PJ, Bowden DW, Efendic S, Brismar K, Gu HF. Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy. *Am J Nephrol*. 2009; 29:244–251. [PubMed: 18802326]
13. Evans JF, Lee JH, Ragolia L. Ang II-induced Ca<sup>2+</sup> influx is mediated by the 1/4/5 subgroup of the transient receptor potential proteins in cultured aortic smooth muscle cells from diabetic Goto-Kakizaki rats. *Mol Cell Endocrinol*. 2009; 302:49–57. [PubMed: 19135126]
14. Niehof M, Borlak J. Hepatic nuclear factor 4 alpha and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy. *Diabetes*. 2008; 57:1069–1077. [PubMed: 18184923]

15. Mita M, Ito K, Taira K, Nakagawa J, Walsh MP, Shoji M. Attenuation of store-operated  $\text{Ca}^{2+}$  entry and enhanced expression of TRPC channels in caudal artery smooth muscle from type 2 diabetic Goto-Kakizaki rats. *Clin Exp Pharmacol Physiol*. 2010; 37:670–678. [PubMed: 20337661]
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001; 414:813–820. [PubMed: 11742414]
17. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q; results of novel discordant sib-pair analysis. *Diabetes*. 1998; 47:1164–1169. [PubMed: 9648845]
18. Freedman BI, Bowden DW, Sale MM, Langefeld CD, Rich SS. Genetic susceptibility contributes to renal and cardiovascular complications of type 2 diabetes mellitus. *Hypertension*. 2006; 48:8–13. [PubMed: 16735643]
19. McKnight AJ, Maxwell AP, Sawcer S, Compston A, Setakis E, Patterson CC, Brady HR, Savage DA. A genome-wide diabetic nephropathy: a microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. *J Am Soc Nephrol*. 2006; 17:831–836. [PubMed: 16467450]
20. Du J, Sours-Brothers S, Coleman R, Ding M, Graham S, Kong D, Ma R. Canonical transient receptor potential 1 channel is involved in contractile function of glomerular mesangial cells. *J Am Soc Nephrol*. 2007; 18:1437–1445. [PubMed: 17389736]
21. Sours S, Du J, Chu S, Zhou JX, Ding M, Ma R. Expression of canonical transient receptor potential (TRPC) proteins in human glomerular mesangial cells. *Am J Physiol Renal Physiol*. 2006; 290:F1507–F1515. [PubMed: 16418302]
22. Graham S, Gorin Y, Abboud HE, Ding M, Lee DY, Shi H, Ding Y, Ma R. Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. *Am J Physiol Cell Physiol*. 2011 in press.
23. Sours-Brothers, S.; Ma, R. *Microcirculation: Function, Malfunction, and Measurement*. Nova Publishers; 2009. Canonical transient receptor potential (TRPC) channels in renal microcirculation; p. 25-38.
24. Nutt LK, O'Neil RG. Effect of elevated glucose on endothelin-induced store-operated and non-store-operated calcium influx in renal mesangial cells. *J Am Soc Nephrol*. 2000; 11:1225–35. [PubMed: 10864578]
25. Whiteside CI, Hurst RD, Stevanovic ZS. Calcium signaling and contractile response of diabetic glomerular mesangial cells. *Kidney Int*. 1995; 48(Suppl 51):S28–S33.
26. Hada SJ, Ferreira AT, Oshiro MEM, Neri R, Schor N. Alteration of cytosolic calcium induced by angiotensin II and norepinephrine in mesangial cells from diabetic rats. *Kidney Int*. 1997; 51:87–93. [PubMed: 8995721]
27. Ambudkar IS.  $\text{Ca}^{2+}$  signaling microdomains: platforms for the assembly and regulation of TRPC channels. *TIPS*. 2006; 27:25–32. [PubMed: 16337693]
28. Hofmann T, Schaefer M, Schultz G, Gudermann T. Subunit composition of mammalian transient receptor potential channels in living cells. *PNAS*. 2002; 99(11):7461–7466. [PubMed: 12032305]
29. Chorzempa A. Type 2 diabetes mellitus and its effect on vascular disease. *J Cardiovas Nurs*. 2006; 21:485–92.
30. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. *Am J Hypertens*. 2001; 14:475–486. [PubMed: 11368471]
31. The National High Blood Pressure Education Program Working Group. national high blood pressure education program working group report on hypertension in diabetes. *Hypertension*. 1994; 23:145–158. [PubMed: 8307622]
32. Bokoch GM, Diebold B, Kim JS, Gianni D. Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. *Antioxid Redox Signal*. 2009; 11:2429–2441. [PubMed: 19358632]
33. Iaguid GJL, Masih-Khan E, Kai S, van Breemen C, Dube GP. Influence of type II diabetes on arterial tone and endothelial function in Murine mesenteric resistance arteries. *J Vas Res*. 2001; 38:578–589.




34. Okon EB, Chung AWY, Rauniyar P, Padilla E, Tejerina T, McManus BM, Luo H, van Breemen C. Compromised arterial function in human type 2 diabetic patients. *Diabetes*. 2005; 54:2415–2423. [PubMed: 16046309]
35. Jarajapu YPR, Guberski DL, Grant MB, Knot HJ. Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat. *Eur J Pharmacol*. 2008; 579:298–307. [PubMed: 18036520]
36. Navedo MF, Takeda Y, Nieves-Cintrón M, Molkentin JD, Santana LF. Elevated  $Ca^{2+}$  sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. *Am J Physiol Cell Physiol*. 2010; 298:C211–C220. [PubMed: 19846755]
37. Yao X, Garland CJ. Recent developments in vascular endothelial cell transient receptor potential channels. *Circ Res*. 2005; 97:853–863. [PubMed: 16254217]
38. Beech DJ. Emerging functions of 10 types of TRP cationic channel in vascular smooth muscle. *Clin Exp Pharmacol Physiol*. 2005; 32:597–603. [PubMed: 16120184]
39. Pedersen SF, Owsianik G, Nilius B. TRP channels: an overview. *Cell Calcium*. 2005; 38:233–252. [PubMed: 16098585]
40. Putney JW. Physiological mechanism of TRPC activation. *Pflugers Arch*. 2005; 451:29–34. [PubMed: 16133266]
41. Putney JW. New molecular players in capacitative  $Ca^{2+}$  entry. *J Cell Science*. 2007; 120:1959–1965. [PubMed: 17478524]
42. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Meyer T. STIM is a  $Ca^{2+}$  store sensor essential for  $Ca^{2+}$ -store-depletion-triggered  $Ca^{2+}$  influx. *Current Biol*. 2005; 15:1235–1241.
43. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, Stauderman KA, Cahalan MD. STIM1 is a  $Ca^{2+}$  sensor that activates CRAC channels and migrates from the  $Ca^{2+}$  store to the plasma membrane. *Nature*. 2005; 437:902–905. [PubMed: 16208375]
44. Zbidi H, Lopez JJ, Amor NB, Bartegi A, Salido GM, Rosado JA. Enhanced expression of STIM1/Orai1 and TRPC3 in platelets from patients with type 2 diabetes mellitus. *Blood Cells Mol Dis*. 2009; 43:211–213. [PubMed: 19447651]
45. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. *Tohoku J Exp Med*. 1976; 119:85–90. [PubMed: 951706]
46. Mita M, Kuramoto T, Ito K, Toguchi-Senrui N, Hishinuma S, Walsh MP, Shoji M. Impairment of  $\alpha 1$ -adrenoceptor-mediated contractile activity in caudal arterial smooth muscle from type 2 diabetic Goto-kakizaki rats. *Clin Exp Pharmacol Physiol*. 2010; 37:350–357. [PubMed: 19793102]
47. Strübing C, Krapivinsky G, Krapivinsky L, Clapham DE. TRPC1 and TRPC5 form a novel cation channel in mammalian brain. *Neuron*. 2001; 29:645–655. [PubMed: 11301024]
48. Zhu X. *TRP*, a novel mammalian gene family essential for agonist-activated capacitative  $Ca^{2+}$  entry. *Cell*. 1996; 85:661–671. [PubMed: 8646775]
49. Andrews KI, Pannirselvam M, Anderson TJ, Jenkins A, Triggle CR, Hill MA. The vascular endothelium in diabetes: a practical target for drug treatment? *Expert Opin Ther Targets*. 2005; 9:101–117. [PubMed: 15757485]
50. Vanhoutte PM. Endothelium and control of vascular function. *Hypertension*. 1998; 13:658–667. [PubMed: 2661425]
51. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. *Lancet*. 1997; 350 (suppl 1):S19–S113.
52. Clark CM, Lee DA. Prevention and treatment of the complication of diabetes mellitus. *N Engl J Med*. 1995; 332:1210–1217. [PubMed: 7700316]
53. Sturek M.  $Ca^{2+}$  regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes. *J Appl Physiol*. 2011; 111:573–586. [PubMed: 21596923]
54. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. *Nature*. 2008; 451:904–913. [PubMed: 18288179]
55. Venkatachalam K, Zheng F, Gill DL. Regulation of canonical transient receptor potential (TRPC) channel function by diacylglycerol and protein kinase C. *J Biol Chem*. 2003; 278(31):29031–29040. [PubMed: 12721302]
56. Leung FP, yung LM, Yao X, Laher I, Huang Y. Store-operated calcium entry in vascular smooth muscle. *Br J Pharmacol*. 2007; 153:846–857. [PubMed: 17876304]

57. Beech DJ. Ion channel switching and activation in smooth-muscle cells of occlusive vascular diseases. *Biochem Soc Trans.* 2007; 35:890–894. [PubMed: 17956239]
58. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes Care.* 2005; 28:1769–1778. [PubMed: 15983333]
59. Edwards JM, Neeb ZP, Alloosh MA, Long X, Bratz IN, Peller CR, Byrd JP, Kumar S, Obukhov AG, Sturek M. Exercise training decreases store-operated  $\text{Ca}^{2+}$  entry associated with metabolic syndrome and coronary atherosclerosis. *Cardiovas Res.* 2010; 85:631–640.
60. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2007; 27:2292–2301. [PubMed: 17673705]
61. Smedlund K, Vazquez G. Involvement of native TRPC3 proteins in ATP-dependent expression of VCAM-1 and monocyte adherence in coronary artery endothelial cells. *Arterioscler Thromb Vasc Biol.* 2008; 28:2049–2055. [PubMed: 18787184]
62. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity.* 2003; 19:71–82. [PubMed: 12871640]
63. Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC, Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM. Functional role of  $\text{CD11c}^{+}$  monocytes in atherogenesis associated with hypercholesterolemia. *Circulation.* 2009; 119:2708–2717. [PubMed: 19433759]
64. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. *Ann Intern Med.* 2004; 141:413–420. [PubMed: 15381514]
65. Carr ME. Diabetes mellitus: a hypercoagulable state. *J Diabetes Complications.* 2001; 15:44–54. [PubMed: 11259926]
66. Saavedra FR, Redondo PC, Hernandez-Cruz JM, Salido GM, Pariente JA, Rosado JA. Store-operated  $\text{Ca}^{2+}$  entry and tyrosine kinase pp60 (src) hyperactivity are modulated by hyperglycemia in platelets from patients with non-insulin-dependent diabetes mellitus. *Arch Biochem Biophys.* 2004; 432:261–268. [PubMed: 15542065]
67. Jardin I, Redondo PC, Salido GM, Rosado JA. Phosphatidylinositol 4,5-bisphosphate enhances store-operated calcium entry through hTRPC6 channel in human platelets. *Biochim Biophys Acta.* 2008; 1783:84–97. [PubMed: 17719101]
68. Braum A, Varga-Szabo D, Kleinschnitz C, Pleines I, Bender M, Austinat M, Bosl M, Stoll G, Nieswandt B. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. *Blood.* 2009; 113:2056–2063. [PubMed: 18832659]
69. Salido GM, Sage SO, Rosado JA. Biochemical and functional properties of the store-operated  $\text{Ca}^{2+}$  channels. *Cell signal.* 2009; 21:457–461. [PubMed: 19049864]
70. Brownlow SL, Sage SO. Transient receptor potential protein subunit assembly and membrane distribution in human platelets. *Thromb Haemost.* 2005; 94:839–845. [PubMed: 16270640]
71. Bouaziz A, Salido S, Linares-Palomino PJ, Sanchez A, Altarejos J, Bartegi A, Salido GM, Rosado JA. Cinnamtannin B-1 from bay wood reduces abnormal intracellular  $\text{Ca}^{2+}$  homeostasis and platelet hyperaggregability in type 2 diabetes mellitus patients. *Arch Biochem Biophys.* 2007; 457:235–242. [PubMed: 17118329]
72. Liu D, Maier A, Scholze A, Rauch U, Boltzen U, Zhao Z, Zhu Z, Tepel M. High glucose enhances transient receptor potential channel canonical type 6 (TRPC6)-dependent calcium influx in human platelets via phosphatidylinositol 3-kinase-dependent pathway. *Arterioscler Thromb Vasc Biol.* 2008; 28:746–751. [PubMed: 18258814]
73. Bivalacqua TJ, Usta MF, Champion HC, Adams D, McNamara DB, Abdel-Mageed AB, Kadowitz WJG. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. *J Urol.* 2003; 169:1911–1917. [PubMed: 12686872]
74. Celtek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S. Selective nitroergic neurodegeneration in diabetes mellitus—a nitric oxide-dependent phenomenon. *Br J Pharmacol.* 1999; 128:1804–1812. [PubMed: 10588937]
75. Rubin A, Babbott D. Impotence and diabetes mellitus. *JAMA.* 1958; 168:498–500.

76. Jung JH, Kim BJ, Chae MR, Kam SC, Jeon JH, So I, Chung KH, Lee SW. Gene transfer of TRPC6<sup>DN</sup> (dominant negative) restores erectile function in diabetic rats. *J Sex Med.* 2010; 7:1126–1138. [PubMed: 20059667]
77. Newton AC. Protein kinase C: structure, function, and regulation. *J Biol Chem.* 1995; 270(48): 28495–28498. [PubMed: 7499357]
78. Ma R, Pluznick J, Kudlacek P, Sansom SC. Protein kinase C activates store-operated Ca<sup>2+</sup> channels in human glomerular mesangial cells. *J Biol Chem.* 2001; 276(28):25759–25765. [PubMed: 11352899]
79. Ma R, Kudlacek PE, Sansom SC. Protein kinase C $\alpha$  participates in activation of store-operated Ca<sup>2+</sup> channels in human glomerular mesangial cells. *Am J Physiol Cell Physiol.* 2002; 283:C1390–C1398. [PubMed: 12372800]
80. Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. *Am J Physiol Renal Physiol.* 2002; 282:F975–F980. [PubMed: 11997313]
81. Hidalgo C, Donoso P. Crosstalk between calcium and redox signaling: from molecular mechanisms to health implications. *Antioxid Redox Signal.* 2008; 10:1275–1312. [PubMed: 18377233]
82. Hool LC, Corry B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. *Antioxid Redox signal.* 2007; 9:409–435. [PubMed: 17280484]
83. Rhee SG, Chang TS, Bae YS, Lee SR, Kang SW. Cellular regulation by hydrogen peroxide. *J Am Soc Nephrol.* 2003; 14:S211–S215. [PubMed: 12874433]
84. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. *Life Scien.* 2009; 84:705–712.
85. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. *Exp Biol Med.* 2008; 233:4–11.
86. Kim NH, Rincon-Choles H, Bhandari B, Choudhury GG, Abboud HE, Gorin Y. Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. *Am J Physiol Renal Physiol.* 2006; 290:F741–F751. [PubMed: 16234311]
87. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen specie-regulated signaling pathways in diabetic nephropathy. *J Am Soc Nephrol.* 2003; 14:S241–S245. [PubMed: 12874439]

## Involvement of TRPC Channels in Diabetic Vasculopathy



**Figure 1.**

Possible mechanisms for contributions of TRPC channels in vascular cells, circulating monocytes and platelets to diabetic vasculopathy. During diabetes, an upregulation of TRPCs in vascular smooth muscle cells (VSMC) increases intracellular  $\text{Ca}^{2+}$  levels which then promotes contraction and possibly proliferation in these cells. In endothelial cells (EC), an augmentation of TRPC channel-mediated  $\text{Ca}^{2+}$  entry impairs the integrity of the endothelium, which consequently increases the permeability of the vascular endothelium. An elevated intracellular  $\text{Ca}^{2+}$  level from TRPC channels in ECs also increases the cell surface expression of vascular cell adhesion molecule-1 (VCAM-1) which promotes monocyte adhesion to the endothelium. An increase in TRPC channel-mediated  $\text{Ca}^{2+}$  influx in monocytes (M) stimulates the migration and adherence of monocytes to the vascular endothelium, which is a key step for initiation and the progression of atherosclerosis. Furthermore, enhanced  $\text{Ca}^{2+}$  entry through TRPC channels in platelets (P) results in hyperactivity and hyperaggregability of the platelets, which facilitates the development of cardiovascular complications.

Table 1

Effect of diabetes or high glucose (HG) on TRPC expression

TRPC Isoform	Species	Animal Model	Tissue/Cell Type	mRNA or Protein	Time in HG/Diabetes	HG Conc.	TRPC changes	Citation
TRPC1	Bovine	N/A	Aortic endothelial cells	Protein	72 hours	25 mM	Increased	10
TRPC3	Bovine	N/A	Aortic endothelial cells	Protein	72 hours	25 mM	no change	10
TRPC4	Bovine	N/A	Aortic endothelial cells	Protein	72 hours	25 mM	no change	10
TRPC6	Bovine	N/A	Aortic endothelial cells	Protein	72 hours	25 mM	no change	10
TRPC1	Human	N/A	Saphenous vein	Both	11.5 years	6.9 mM	protein decreased	9
TRPC4	Human	N/A	Saphenous vein	Both	11.5 years	6.9 mM	mRNA increased	9
TRPC6	Human	N/A	Saphenous vein	Both	11.5 years	6.9 mM	protein decreased	9
TRPC1	Rat	Goto-Kakizaki	Vascular smooth muscle cells	Both	8 weeks	N/A	mRNA decreased	13
TRPC4	Rat	Goto-Kakizaki	Vascular smooth muscle cells	Both	8 weeks	N/A	Protein increased	13
TRPC5	Rat	Goto-Kakizaki	Vascular smooth muscle cells	Both	8 weeks	N/A	No change	13
TRPC6	Rat	Goto-Kakizaki	Vascular smooth muscle cells	Both	8 weeks	N/A	both decreased	13
TRPC1	Human	N/A	Cultured mesangial cells	protein	7 days	30 mM	No change	5
TRPC3	Human	N/A	Cultured mesangial cells	protein	7 days	30 mM	No change	5
TRPC6	Human	N/A	Cultured mesangial cells	Both	7 days	30 mM	Both decreased	5
TRPC1	Rat	Streptozotocin	Kidney glomeruli	Protein	2 weeks	>300 mg/dL	No change	5
TRPC6	Rat	Streptozotocin	Kidney glomeruli	Protein	2 weeks	>300 mg/dL	Decreased	5, 22
TRPC1	Human	N/A	Platelets	Protein	N/A	212 mg/dL	No change	72
TRPC3	Human	N/A	Platelets	Protein	N/A	212 mg/dL	No change	72
TRPC4	Human	N/A	Platelets	Protein	N/A	212 mg/dL	No change	72
TRPC5	Human	N/A	Platelets	Protein	N/A	212 mg/dL	No change	72
TRPC6	Human	N/A	Platelets	Protein	N/A	212 mg/dL	Increased	72
TRPC1	Rat	Goto-Kakizaki	Arterial smooth muscle	Protein	12 weeks	N/A	Increased	15
TRPC3	Rat	Goto-Kakizaki	Arterial smooth muscle	Protein	12 weeks	N/A	No change	15
TRPC6	Rat	Goto-Kakizaki	Arterial smooth muscle	Protein	12 weeks	N/A	Increased	15
TRPC1	Swine	Ossabaw	Coronary arterial smooth muscle	Protein	58 weeks	83 mg/dL	Increased	59
TRPC1	Rat	Zucker obese	Kidney & Liver	mRNA	14 weeks	30 mM	Decreased	14
TRPC1	Rat	Streptozotocin	Kidney & Liver	mRNA	24 weeks	>400 mg/dL	Decreased	14
TRPC1	Human	N/A	Kidney	Protein	N/A	N/A	Decreased	14
TRPC1	Human	N/A	Cultured monocytes	mRNA	4 hours	30 mM	Increased	11

<u>TRPC Isoform</u>	<u>Species</u>	<u>Animal Model</u>	<u>Tissue/Cell Type</u>	<u>mRNA or Protein</u>	<u>Time in HG/Diabetes</u>	<u>HG Conc.</u>	<u>TRPC changes</u>	<u>Citation</u>
TRPC3	Human	N/A	Fresh monocytes	Both	4 hours	N/A	Increased	11
TRPC5	Human	N/A	Cultured monocytes	mRNA	4 hours	30 mM	Increased	11
TRPC6	Human	N/A	Fresh monocytes	Both	4 hours	N/A	Increased	11
TRPC1	Human	N/A	Platelets	Protein	N/A	210 mg/dL	No change	44
TRPC3	Human	N/A	Platelets	Protein	N/A	210 mg/dL	Increased	44
TRPC6	Human	N/A	Platelets	Protein	N/A	210 mg/dL	Decreased	44
TRPC1	Mice	db/db	Whole kidney	mRNA	26 weeks	21 mM	Increased	12